menu
    • menu
    [{"orgOrder":0,"company":"Alpha-9 Oncology","sponsor":"Lightspeed Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Alpha-9 Oncology","amount2":0.17999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Oral","sponsorNew":"Alpha-9 Oncology \/ Lightspeed Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Alpha-9 Oncology \/ Lightspeed Venture Partners"},{"orgOrder":0,"company":"Alpha-9 Oncology","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Alpha-9 Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha-9 Oncology \/ Alpha-9 Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Alpha-9 Oncology \/ Alpha-9 Oncology"}]

    Find Clinical Drug Pipeline Developments & Deals by Alpha-9 Oncology

    Menu

    Alpha-9 Oncology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alpha-9 Oncology

                            Canada arrow
                            iPHEX India
                            Not Confirmed

                            Alpha-9 Oncology

                            Canada arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Lightspeed Venture Partners

                            Deal Size : $175.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Alpha-9 Oncology Raises $175M to Advance Radiopharmaceutical Pipeline

                            Details : The proceeds will advance the pipeline of targeted radiopharmaceuticals through clinical studies across multiple tumors and discovery stage assets to clinic-ready development candidates.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 23, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Lightspeed Venture Partners

                            Deal Size : $175.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alpha-9 Oncology

                            Canada arrow
                            iPHEX India
                            Not Confirmed

                            Alpha-9 Oncology

                            Canada arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Isotope Technologies Munich

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ITM and Alpha-9 Announce Global Supply Agreement for Clinical Radiopharmaceuticals

                            Details : Through collaboration, ITM will supply its medical radioisotope, non-carrier-added Lutetium-177 (n.c.a. 177Lu) for Alpha-9's Lutetium-based candidates for the treatment of cancer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 30, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Isotope Technologies Munich

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth